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[pyr1]apelin-13 is the predominant apelin peptide isoform in the human cardiovascular system and 
plasma. to date, few studies have investigated [pyr1]apelin-13 metabolism in vivo in rats with no studies 
examining its stability in humans. We therefore aimed to develop an Lc-MS/MS method for detection 
and quantification of intact [Pyr1]apelin-13 and have used this method to identify the metabolites 
generated in vivo in humans. [pyr1]apelin-13 (135 nmol/min) was infused into six healthy human 
volunteers for 120 minutes and blood collected at time 0 and 120 minutes after infusion. Plasma was 
extracted in the presence of guanidine hydrochloride and analysed by Lc-MS/MS. Here we report a 
highly sensitive, robust and reproducible method for quantification of intact [Pyr1]apelin-13 and its 
metabolites in human plasma. Using this method, we showed that the circulating concentration of 
intact peptide was 58.3 ± 10.5 ng/ml after 120 minutes infusion. We demonstrated for the first time 
that in humans, [pyr1]apelin-13 was cleaved from both termini but the C-terminal was more susceptible 
to cleavage. Consequently, of the metabolites identified, [Pyr1]apelin-13(1–12), [pyr1]apelin-13(1–10) and 
[pyr1]apelin-13(1–6) were the most abundant. these data suggest that apelin peptides designed for use as 
cardiovascular therapeutics, should include modifications that minimise C-terminal cleavage.
Apelin is an endogenous ligand of the apelin receptor, initially characterised from bovine stomach extracts as a 
77-amino acid preproprotein1. The prepro-apelin is further cleaved into shorter but functional fragments includ-
ing apelin-36, apelin-17, apelin-13 and [Pyr1]apelin-13 that contain an evolutionary conserved 12-amino acid 
C-terminal1–3. [Pyr1]apelin-13 was subsequently identified as the most predominant isoform of the apelin family 
of peptides in the cardiovascular system4,5, and the major circulating form of the peptide6.
In the cardiovascular system, apelin is the most potent endogenous inotropic agent yet identified4. Apelin 
modulates vascular tone in vivo, decreasing blood pressure when infused into rats and dilating resistance ves-
sels when infused into human forearm7–9. In vitro, apelin causes nitric oxide-dependent vasodilation of human 
splanchnic artery10, although a nitric oxide-independent, prostanoid dependent vasodilation in humans has 
been reported4. Apelin acted as a vasoconstrictor in endothelium denuded vessels via a direct action on vascular 
smooth muscle cells whilst also acting as a potent angiogenic factor and mitogen of endothelial cells4,11. Based on 
these beneficial effects, apelin was proposed as a potential therapeutic target in cardiovascular diseases. For exam-
ple, apelin administration showed cardioprotective effects in heart failure12, and ameliorated the development of 
pulmonary arterial hypertension in rats13,14 and humans15. In addition, the protective effects of apelin has been 
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reported in metabolic diseases where it decreased adiposity, serum insulin and increased insulin sensitivity16,17; 
and in renal diseases where it decreased acute renal injury and fibrosis18. It has recently emerged that apelin has 
pro-tumorigenic effects in various cancer models possibly by promoting angiogenesis and that inhibition of the 
apelin pathway was protective against tumour growth14,19. However, these beneficial effects of apelin peptides are 
limited by the rapid in vivo metabolism.
Previous studies investigating the metabolism of apelin peptides were largely conducted in plasma in vitro 
or in rodent models neither of which may represent metabolism in humans. These studies demonstrated that 
apelin peptides are very labile in plasma with a half-life of less than 1–5 minutes in vitro20–24. This plasma insta-
bility has to date been attributed the enzymatic activity of neprilysin25 and angiotensin converting enzyme II 
(ACE2)22–24, and more recently plasma kallikrein26,27. Similarly, another recent study reported more rapid degra-
dation of [Pyr1]apelin-13 in rat and mouse plasma when compared to dog, monkey and human plasma in vitro28. 
The authors also confirmed their findings in vivo in rat and mouse, and identified N-terminal metabolites of the 
peptide, particularly apelin-7 that was most abundant28. This study therefore highlighted species differences in 
the repertoire of proteases circulating and present in rodent and higher mammalian systems. However, to date 
no studies have investigated the metabolism of apelin peptides in vivo in humans. The aim of this study was to 
develop a highly sensitive mass spectrometry based method for detection and quantification of apelin peptides 
in plasma. We used this method to measure intact [Pyr1]apelin-13 and its metabolites generated in humans, 
following a constant 120 minutes infusion of the peptide. We found that [Pyr1]apelin-13 was cleaved into smaller 
fragments from both termini but that the C-terminal was more susceptible. We identified the biologically active 
C-terminal cleavage product, [Pyr1]apelin-13(1–12), as the most abundant, as well as identifying novel metabolites 
including [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6).
Results
Precision and accuracy of the extraction and quantification method. An 8-point calibration line 
was generated for [Pyr1]apelin-13 in human plasma (r2 = 0.99, data not shown), with a lower limit of quanti-
fication (LLOQ) of 1 ng/ml. The relative errors (% RE) for all calibration standards were less than 20% at the 
LLOQ and below 15% at other levels, conforming with typical bioanalytical method validation guidelines29. The 
precision and accuracy of the QC samples showed that the method was robust and accurate. The LLOQ samples 
returned a coefficient of variation (%CV) of 8.0 and %RE of 15.5, whilst the other QC levels had %CV’s below 6.1 
and %RE’s below 8.4. Representative chromatograms obtained from calibration standards 1 and 8 are shown in 
Fig. 1.
Figure 1. Representative chromatogram of calibration standards. LLOQ standard shows peaks corresponding 
to [Pyr1]apelin-13 at 1 ng/ml (A) and [Pyr1]apelin-13 internal standard at 25 ng/ml (B). Upper limit of 
quantification shows peaks corresponding to [Pyr1]apelin-13 (C) and [Pyr1]apelin-13 internal standard at  
25 ng/ml (D). MRM = multiple reaction monitoring.
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plasma concentrations of [pyr1]apelin-13 in healthy human volunteer samples. In samples 
obtained before infusion of [Pyr1]apelin-13, no chromatographic peak was observed for the peptide (Fig. 2A,B). 
Samples obtained at the end of the infusion (t = 120 minutes) showed strong peaks at 3.68 minutes corresponding 
to [Pyr1]apelin-13 (Fig. 2C,D). The measured concentration of [Pyr1]apelin-13 in these samples after 120 min-
utes was 58.3 ± 10.5 ng/ml. Additionally, data from the six donor control samples that did not receive [Pyr1]
apelin infusion showed that the endogenous levels of [Pyr1]apelin in these samples were below the LLOQ (see 
Supplementary Fig. 1). The peak height obtained from the chromatogram of these donor samples had a maximum 
height that was 19.8% of that seen in the LLOQ and so was considered as blank for quantitative purposes based on 
the FDA method validation guidelines for demonstrating selectivity of an LC-MS methodology30.
Identification of potential C-terminal metabolites of [Pyr1]apelin-13. In order to identify poten-
tial metabolites of [Pyr1]apelin-13 generated during the 120 minutes infusion period, samples were re-analysed 
using a high resolution mass spectrometer. Full scan LC-MS data were interrogated for potential [Pyr1]apelin-13 
derived metabolites by comparing extracted ion chromatograms for each analyte in the 0 and 120 minute samples 
in the Qualbrowser software package (Thermofisher). Peptides that were identified in the 120 minute samples 
were mainly generated by the loss of C-terminal amino acids (Fig. 3A). Their relative abundance in the samples 
are displayed in Fig. 3B. Notably, the most abundant fragments were [Pyr1]apelin-13(1–12) (known to be biologi-
cally active24), [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6). Other metabolites identified, although at lower levels 
(<10% of parent [Pyr1]apelin-13) included [Pyr1]apelin-13(1–8), [Pyr1]apelin-13(1–7) and [Pyr1]apelin-13(1–5) that 
are likely to be biologically inactive. The chromatographic spectra corresponding to each of these metabolites 
are shown in Fig. 4A–G. In addition to [Pyr1]apelin-13(1–12), the most abundant metabolite identified, [Pyr1]
apelin-13(1–10) (Fig. 5) and [Pyr1]apelin-13(1–6) (Fig. 6) were present at a sufficient level to generate suitable product 
ion spectra allowing experimentally acquired fragments to be matched against theoretical fragments from the 
peptide sequence. The relative mass accuracy of all potential metabolites were generated and the experimental 
values were all within 1 ppm of expected values, whilst the mass accuracy of the parent peptide had the highest 
value of 1.3 ppm.
Oxidation of the methionine residue in [Pyr1]apelin-13 was identified, however since this modification was 
also observed in the extracted standards, it could not be ascertained if they occurred in vivo or as an artefact of 
the extraction process.
Identification of potential N-terminal metabolites of [Pyr1]apelin-13. Using the same approach 
described above, several N-terminal metabolites of [Pyr1]apelin-13 were identified (Fig. 7). Of note, the peak 
areas of these fragments were lower compared to those observed for the C-terminal fragments. The most abun-
dant N-terminal fragments observed were [Pyr1]apelin-13(6–13), [Pyr1]apelin-13(11–13), [Pyr1]apelin-13(7–13) and 
Figure 2. Representative chromatogram for [Pyr1]apelin-13 and its internal standard in volunteer samples. 
(A,B) chromatograms for samples obtained at t = 0 minutes; (C,D) chromatograms for samples obtained at 
t = 120 minutes. (A) no [Pyr1]apelin-13 was detected; (B) [Pyr1]apelin-13 internal standard chromatogram 
showing 3.67 minutes retention time; (C) [Pyr1]apelin-13 chromatogram showing 3.68 minutes retention time; 
(D) [Pyr1]apelin-13 internal standard. MRM = multiple reaction monitoring.
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[Pyr1]apelin-13(10–13) (Fig. 7A,B). Other fragments present but low in abundance include [Pyr1]apelin-13(3–13), 
[Pyr1]apelin-13(4–13) and [Pyr1]apelin-13(8–13). The mass accuracy of the experimentally acquired monoisotopic 
m/z for these metabolites are shown in Fig. 8, and were all within 0.9 ppm of expected values.
Discussion
We have developed and validated a high resolution LC-MS/MS method for detection and quantification of [Pyr1]
apelin-13 and relative quantification of its metabolites in vivo in human plasma. We have shown that this method 
was robust, reproducible and had a high sensitivity for [Pyr1]apelin-13 with an LLOQ of 1 ng/ml. Using this 
method, we have quantified the intact peptide after constant infusion for 120 minutes into healthy volunteers and 
showed for the first time that in humans in vivo, [Pyr1]apelin-13 was cleaved from both the N- and C-termini, 
with the C-terminus being the most susceptible to proteolytic activity. The most abundant metabolite identified 
by this method was [Pyr1]apelin-13(1–12) but very high levels of [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6) were 
also detected, the sequences of which were confirmed using tandem mass spectrometry and manual product ion 
matching.
The discovery that [Pyr1]apelin-13 was cleaved from both ends was unexpected since to date only cleavage 
from the C-terminus has been described23,24. Our findings may therefore better explain the extremely unsta-
ble nature of apelin peptides in plasma6,28,31. It is worth noting that the C-terminus was more susceptible to 
proteolytic activity than the N-terminus, whose metabolites were present at approximately 20-fold lower levels. 
This may partly be explained by the pyroglutamylation of the N-terminus which may protect this region from 
enzymatic activity to some degree. The N-terminus of [Pyr1]apelin-13 also contains the RPRL motif critical for 
binding to the apelin receptor32, hence any cleavage from this direction is likely to profoundly affect the affinity 
of these N-terminal fragments for the receptor. A previous study showed in vitro that neprilysin cleaves [Pyr1]
apelin-13 between Arg4 and Leu5 and between Leu5 and Ser6 amino acids25, thereby making neprilysin the first 
enzyme identified to date that completely inactivates the peptide. Importantly, we have now shown in this study 
the presence of one of these proposed neprilysin cleavage products, [Pyr1]apelin-13(6–13), in humans in vivo 
Figure 3. Relative abundance of [Pyr1]apelin-13 C-terminal metabolites identified from human plasma 
identified by LC-MS/MS. (A) peptide sequences of [Pyr1]apelin-13 metabolites identified in human plasma (the 
RPRL motif required for receptor binding was indicated by (*); (B) relative peak area of the metabolites (n = 6, 
data represent mean ± SD).
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Figure 4. Representative chromatogram of [Pyr1]apelin-13 and its C-terminal metabolites identified in 
human plasma. The extracted ion chromatogram for [Pyr1]apelin-13 shows the m/z for the first 13C ion, as the 
extracted chromatogram for the monoisotopic peak had significant background noise throughout. (A) [Pyr1]
apelin-13 with 8.80 minutes retention time; (B) [Pyr1]apelin-13(1–12) with 6.26 minutes retention time; (C) [Pyr1]
apelin-13(1–10) with 4.29 minutes retention time; (D) [Pyr1]apelin-13(1–8) with 3.25 minutes retention time; (E) 
[Pyr1]apelin-13(1–7) with 4.22 minutes retention time; (F) [Pyr1]apelin-13(1–6) with 5.09 retention time; (G) [Pyr1]
apelin-13(1–5) with 5.88 minutes retention time. These data were acquired using Orbitrap Mass spectrometer 
used for metabolite identification. The mass accuracy of the experimentally acquired monoisotopic peak was 
calculated for each potential metabolite, and is included along with the 13C isotopic cluster for each peptide with 
their corresponding chromatogram.
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with additional evidence for cleavage of the scissile bond between Leu5 and Ser6 given by the detection of the 
C-terminal fragment, [Pyr1]apelin-13(1–5). To date very few studies have investigated the metabolism of peptides 
in vivo in humans. Interestingly, like [Pyr1]apelin-13, arginine vasopressin was also proposed to be cleaved in vivo 
from both the C- and N- termini, with carboxypeptidase and post-proline enzymes cleaving the C-terminus of 
arginine vasopressin, while aminopeptidases cleaved the N-terminal region33–35. In contrast, other in vivo studies 
of this nature identified only a single terminus cleavage of Peptide YY36, growth hormone-releasing hormone37, 
liraglutide, a glucagon-like peptide-1 (GLP-1) analogue38 and big endothelin-139.
Previous in vitro studies in plasma, suggested that [Pyr1]apelin-13(1–12) was a metabolite of [Pyr1]apelin-13 
produced by the enzymatic activity of ACE2 resulting in the removal of the C-terminal phenylalanine20,22–24,40. 
However, it was unclear whether this metabolite retained biological activity at the apelin receptor. One study 
argued that [Pyr1]apelin-13(1–12) had reduced biological activity compared to the native [Pyr1]apelin-13 as meas-
ured by its hypotensive effects in mice23. However, Yang et al.24 demonstrated that the ACE2 metabolite, [Pyr1]
apelin-13(1–12) contracted human saphenous vein with sub-nanomolar potency and was a potent positive ino-
trope in paced mouse and human heart ex vivo. The authors demonstrated [Pyr1]apelin-13(1–12) was present 
endogenously in the endothelium of human heart and lungs, and went on to show that it was biologically active 
in vivo in humans and rodents24. Similarly, a previous study reported that [Pyr1]apelin-13 was cleaved to [Pyr1]
apelin-13(1–12) in vivo in rats22. Consistent with these studies, our work now provides clear evidence that [Pyr1]
apelin-13(1–12) is produced endogenously in human plasma in vivo possibly via the activity of ACE2.
[Pyr1]apelin-13 was also cleaved between Pro10 and Met11 and between Ser6 and His7 resulting in genera-
tion of [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6) but the enzyme responsible for producing these metabo-
lites remains unknown. The corresponding N-terminal fragments of these C-terminal metabolites [Pyr1]
Figure 5. Product ion mass spectrum of [Pyr1]apelin-13(1–10). The major ions identified are shown in brackets.
Figure 6. Product ion mass spectrum of [Pyr1]apelin-13(1–6). The major ions identified are shown in brackets.
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apelin-13(11–13) and [Pyr1]apelin-13(7–13), were also identified. These data were consistent with a previous in vivo 
study in male rats which also identified the C-terminal metabolites22. The authors reported on the accumulation 
of [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6) signals with time as [Pyr1]apelin-13 and [Pyr1]apelin-13(1–12) sig-
nals decreased, suggesting that following ACE2 cleavage of [Pyr1]apelin-13 to [Pyr1]apelin-13(1–12), other uniden-
tified enzymes subsequently cleave both [Pyr1]apelin-13 and [Pyr1]apelin-12 into [Pyr1]apelin-13(1–10) and [Pyr1]
apelin-13(1–6). These metabolites [Pyr1]apelin-13(1–10) and [Pyr1]apelin-13(1–6), retained the RPRL motif required 
for binding32, although it is unclear if they retain biological activity. Taken together, these findings may suggest 
that there is at least some common metabolic pathways for [Pyr1]apelin-13 in rats and humans in vivo. Further 
studies are required to identify the specific proteases involved.
Inhibition of degradative enzymes is a well-established strategy to generate therapeutic agents. ACE2 is an 
important member of the renin-angiotensin system that converts angiotensin-II to angiotensin 1–7, with the 
latter mediating vasodilatation, anti-proliferation, anti-apoptosis and anti-fibrotic effects41. In addition, ACE2 
has been implicated in heart failure42,43, diabetic nephropathy44,45, acute lung failure46, lung injury induced by 
the lethal avian influenza A H5N1 virus47, respiratory syncytial virus48 and severe acute respiratory syndrome 
(SARS)46. Recently, GSK developed a recombinant human ACE2, GSK2586881 for treatment of acute respiratory 
distress syndrome (ARDS) and showed that this molecule was well-tolerated in clinical trials49. Corroborating on 
this, apelin signalling induces ACE2 expression in failing hearts12, and protects against lung injury in experimen-
tal models of acute respiratory distress syndrome50, possibly by inhibiting the NF-κB pathway and components of 
the inflammasome51. Furthermore, apelin counteracts the effects of angiotensin-II signalling, which is negatively 
regulated by ACE2, suggesting that targeting ACE2 and apelin could be a potentially novel therapeutic strategy 
for treatment of lung injury related pathologies and heart failure.
The beneficial effects of apelin in heart failure are well characterised. Plasma apelin levels have been suggested 
to increase in early stages5 of heart failure but decrease in late stages of the disease52–54. In support of this, heart fail-
ure therapies such has cardiac resynchronisation therapy used to treat refractory chronic heart failure were shown 
to increase plasma apelin suggesting that increased apelin levels are associated with improved therapeutic benefit54. 
Apelin administration increased stroke volume and contractility in failing hearts11, thereby improving the perfor-
mance of the failing heart. Similarly, neprilysin inhibitors have emerged as a pivotal therapeutic strategy for clinical 
management of heart failure due to the role of neprilysin in the degradation of vasoactive peptides including natriu-
retic peptides and bradykinin55. Indeed, neprilysin inhibitors such as sacubitril are used for clinical management of 
heart failure56. Our data may therefore suggest that an additional benefit of neprilysin inhibitors in heart failure is to 
reduce apelin inactivation resulting in beneficial vasodilation, increased contractility and cardiac output. Building 
on these findings, further studies could substitute the amino acids at the neprilysin cleavage sites in [Pyr1]apelin-13 
with unnatural amino acids to improve its resistance to degradation. Indeed, it was recently shown that infusion of 
neprilysin resistant apelin-17 in an established mice model of abdominal aortic aneurysm ameliorated the adverse 
aortic remodelling and aneurysm formation27. Such a strategy was also demonstrated to significantly increase the 
resistance of [Pyr1]apelin-13 and apelin-17 to ACE2 activity22,23, suggesting that this could potentially be a mecha-
nism to improve plasma stability of apelin-based therapeutics for clinical indications. We have recently published 
on an another approach to stabilise apelin peptides in human blood using albumin domain (AlbudAb) antibody 
conjugated to an apelin analogue, MM202 and showed that this peptide was resistant to degradation yet retained 
biological activity at the human apelin receptor in vitro and in vivo9. Therefore, these strategies could in the near 
future result in the development of the first apelin-based therapeutics for treatment of human diseases.
Figure 7. N-terminal metabolites of [Pyr1]apelin-13 identified from human plasma. (A) sequence of [Pyr1]
apelin-13 N-terminal fragments identified, (B) relative abundance of N-terminal metabolites (n = 6, data 
represent mean ± SD). Star on the [Pyr1]apelin-13 residues indicate amino acid residues critical for receptor 
binding.
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In conclusion, apelin peptides have protective roles in cardiovascular diseases, however, any potential thera-
peutic use is impaired by the poor plasma stability of the peptide. In this study, we have developed a highly sen-
sitive method for detection and quantification of [Pyr1]apelin-13 in human plasma. For the first time in humans 
in vivo we have identified as the most abundant metabolite of [Pyr1]apelin-13, the ACE2 cleavage product, [Pyr1]
apelin-13(1–12) that we have previously demonstrated retains significant biological activity in addition to the puta-
tive neprilysin metabolites [Pyr1]apelin-13(4–13) and [Pyr1]apelin-13(6–13). Combined inhibition of ACE2 and 
neprilysin may be a novel strategy to enhance endogenous apelin levels in conditions in which the peptide is 
downregulated. Additionally, these data will inform the design of more stable apelin peptides for therapeutic use.
Material and Method
Materials. [Pyr1]apelin-13 was custom synthesised by Severn Biotech (Kidderminster, England), and analysed 
by mass spectrometry and purity by HPLC analysis (99.2%) dispensed under sterile conditions. Pharmacological 
activity of [Pyr1]apelin-13 was confirmed using in vitro and in vivo assays (Supplementary Figs. 2 and 3). Peptides 
were stored below −40 °C in a monitored freezer until use2. Stable isotope labelled [Pyr1]apelin-13 (pGlu-R-
[U-13C5, 15N-Pro]-R-[U-13C6, 15N-Leu]-SHKGPMPF-acid) was custom synthesised by Cambridge Research 
Biochemicals (Billingham, England). Protein LoBind Eppendorf tubes (Cat No.: 0030108094) and 1 ml pro-
tein LoBind 96-well plate (Cat No.: 0030504216) were purchased from Eppendorf (Stevenage, UK), and Oasis 
HLB Prime µ-Elution 96-well plates were purchased from Waters (Waters, Wilmslow, UK; Cat No.: 186008052). 
Acetonitrile (ACN) (Cat. No.: 270717) and glacial acetic acid (Cat. No.: 33209-1L) were purchased from Sigma 
Aldrich (Saint Louis, USA), methanol (Cat. No.: 10675112) and 0.1% formic acid (FA) in water (%v/v) (Cat. 
No.: LS118-212) were purchased from Fisher Scientific (New Hampshire, USA). ACQUITY UPLC HSS T3 
1.8 μm 2.1 × 50 mm column (Cat No.: 186003538) used for the LC-MS/MS analysis was obtained from Waters 
(Wilmslow, UK).
Study protocol. This study was registered on Clinicaltrials.gov (NCT03449251) and carried out with eth-
ical approval from the Yorkshire & The Humber – Sheffield Research Ethics Committee (REC reference 18/
YH/0010). All participants gave written informed consent and studies adhered to the Declaration of Helsinki. Six 
Figure 8. Representative chromatogram of the N-terminal metabolites of [Pyr1]apelin-13 identified in human 
plasma. (A) [Pyr1]apelin-13(6–13) with retention time of 8.01 minutes, (B) [Pyr1]apelin-13(7–13) with retention 
time of 8.08 minutes, (C) [Pyr1]apelin-13(8–13) with retention time of 9.35 minutes, (D) [Pyr1]apelin-13(10–13) 
with retention time of 10.45 minutes, (E) [Pyr1]apelin-13(11–13) with retention time of 9.32 minutes. The mass 
accuracy of the experimentally acquired monoisotopic peak was calculated for each potential metabolite, and is 
included along with the 13C isotopic cluster for each peptide with their corresponding chromatogram.
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healthy volunteers (3 male and 3 female, mean age 43.8 ± 6.9, with body mass index within the normal range of 
23.0 ± 1.0) were recruited for infusion. Volunteers were fasted and were lying supine with their heads supported 
in a quiet, temperature controlled (23–25 °C) room for the duration of the study. Following a period of acclima-
tisation, the first sample of venous blood was obtained from the arm contralateral to the arm used for infusion of 
apelin. Vials containing [Pyr1]apelin-13 were allowed to warm to room temperature and diluted with physiolog-
ical saline to produce stock solutions, that were then filtered using a 0.2 µm Portex flat filter (Portex, UK) before 
undergoing serial dilutions with 0.9% sterile saline. There was no loss of apelin following this filtration proce-
dure. Volunteers were infused with a concentration of 135 nmol/min of [Pyr1]apelin-13, at a rate of 1 ml/min 
for 120 minutes, using a syringe pump, equipped with a 50 ml syringe and 16 gauge catheter. The second venous 
sample was obtained immediately after the end of the infusion. Blood samples were collected into 2.6 ml EDTA 
tubes, immediately put on wet ice and centrifuged for 7 minutes at ~4 °C, 4000 rpm and stored a −70 °C, prior 
to analysis. A previous study had used a concentration of up to 100 nmol/min for systemic infusion, where they 
obtained a therapeutic response in patients with pulmonary arterial hypertension and the highest dose was well 
tolerated15. The dose chosen of 135 nmol/min of [Pyr1]apelin-13, was slightly higher in order to identify possible 
metabolites. Additional control samples were obtained from 6 donors (3 male and 3 female) within a similar age 
group who did not receive the apelin infusion for comparison.
[pyr1]apelin-13 LC-MS/MS and SRM based detection method development. An LC-MS/MS 
method was developed for [Pyr1]apelin-13 and its stable isotope labelled [Pyr1]apelin-13 analogue. LC-MS/MS 
instrumentation used for the quantitation of [Pyr1]apelin-13 included a H-Class Acquity (Waters) attached to 
a TQ-XS triple quadrupole mass spectrometer (Waters). Peptides were separated using a 2.1 × 50 mm 1.8 mm 
particle HSS T3 Acquity column held at 60 °C and flowing at 350 µl/minute. Gradient starting conditions were 
95% A (0.1% FA in water v/v) and 5% B (0.1% FA in ACN). Starting conditions were held for 0.2 minutes before 
raising to 25% B over 4 minutes. The column was flushed with 90% B for 0.8 minutes before returning to starting 
conditions. The total time of each analysis was 7 minutes, with the first 1.2 minutes and last 2.8 minutes diverted 
to waste. The source parameters used included a positive electrospray voltage of 3.0 kV, gas flow of 1000 L/hour, 
desolvation temperature of 600 °C and a cone voltage of 40 V.
A full scan analysis of the peptide showed that the [M + 4 H]4+ charge state was the predominant ion in the 
spectrum as previously described by Mesmin et al.31 in their LC-MS/MS analysis of [Pyr1]apelin-13. Therefore 
this was selected for fragmentation. A product ion spectrum was collected over a range of 100 to 1600 m/z and 
two ions were selected for SRM optimisation (m/z 424.6 and 408.55). The 424.6 ion corresponded to the b11 
fragment and the 408.55 ion was derived from the loss of a methyl-sulphide group from the methionine on the 
b11 ion, as previously described by Mesmin et al.31. Optimal conditions for the two SRM transitions for [Pyr1]
apelin-13 were 384.2/408.55, 384.2/424.6 with collision energy values of 14 and 12 eV respectively. The internal 
standard used the same collision energy but targeted transitions of 387.45/412.88 and 387.45/428.26. Peptide 
peak areas were integrated using the TargetLynx program associated with Masslynx V 4.2 (Waters), and peak area 
ratios were generated against the corresponding stable isotope-labelled internal standard peptide peak.
extraction of [pyr1]apelin-13 from human plasma. Plasma samples were thawed on ice and 50 µl 
transferred into protein LoBind Eppendorf tubes containing 25 µl GuHCl (6 M). A 300 µl aliquot of 80% ACN in 
water (containing 25 ng/ml internal standard) was added to all plasma samples and vortexed before centrifuging 
at 12000 x g for 5 minutes to precipitate plasma proteins. The supernatant was transferred to a 1 ml protein LoBind 
96-well plate and evaporated. Samples were reconstituted in 500 μl 0.1% FA (v/v) and loaded onto an Oasis HLB 
Prime µ-elution 96-well plate (Waters, Wilmslow, UK) and slowly extracted on a positive pressure manifold 
(Waters). The columns were washed with 200 µl of 5% methanol in water with 1% acetic acid (v/v) and eluted 
from the cartridge using 2 × 50 µl of 60% methanol in water with 10% acetic acid (v/v). The eluate was evaporated 
to dryness and reconstituted in 150 µl 0.1% FA (v/v) in water and 10 µl was injected onto the LC-MS/MS system.
precision and accuracy of the extraction method. Blank plasma was pre-incubated at 37 °C for at least 
2 hours, to degrade any endogenous [Pyr1]apelin-13 and used to generate an eight point calibration line of custom 
synthesised [Pyr1]apelin-13 over a range of 1–1000 ng/ml. A 50 µl aliquot of each calibration standard (1, 2, 5, 10, 
50, 100, 900, and 1000 ng/ml) was extracted using the SPE method described above. Four levels of QC were also 
generated (1, 3, 100 and 800 ng/ml) and extracted six times in order to assess the precision and accuracy of the 
method. Calibration line followed a linear fit, and 1/x2 weighting was applied. Recovery of the [Pyr1]apelin-13 
from plasma was assessed by analysing spiked solution before and after extraction at a concentration of 100 ng/ml. 
Plasma samples from six individuals were also extracted to assess the selectivity of the LC-MS/MS method.
Peptide Identification using high-resolution mass spectrometry. Samples were reanalysed on 
a high resolution mass spectrometer to identify potential metabolites from the administered [Pyr1]apelin-13 
peptide. A full scan analysis was performed using a ThermoScientific Ultimate 3000 LC system connected 
to a ThermoScientific Orbitrap Q-Exactive Plus mass spectrometer. Solvents used for the separation were A: 
0.1% FA in water (v/v) and B: 0.1% FA in ACN (v/v). A volume of 30 μl of extract was injected onto a HSS T3 
UPLC™column (2.1 × 50 mm; Waters, Elstree, UK) held at 60 °C and with a flow rate of 300 µL/min. A starting 
condition of 1% B was used to capture the more hydrophilic peptide metabolites, and these were eluted using 
a linear gradient up to 30% B over 16 minutes. The column was washed for 2 minutes at 90% B and returned to 
starting conditions for 2 minutes, totalling a run time of 20 minutes. Mass spectrometry was performed using 
positive electrospray mode with a needle voltage of 3 kV, gas settings of 55 and 10 for sheath gas and aux gas flow 
rates. The temperature of the gas was set at 350 °C and the transfer capillary at 350 °C and a s‐lens value of 70 V. 
Full scan data were acquired over an m/z range of 250–1000, using a resolution of 70,000 and a maximum fill time 
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of 100 ms. Acquired LC-MS data were interrogated for potential [Pyr1]apelin-13 metabolites by searching for all 
potential cleavage products from the parent peptide in the RAW data files using the Qualbrowser software pack-
age (Thermofisher). The m/z values for these peptides at multiple charge states are displayed in Supplementary 
Table 1. The potential [Pyr1]apelin-13 metabolites that were manually identified were subsequently characterised, 
where 30 μl of sample was reinjected using a targeted MS/MS analysis. The potential [Pyr1]apelin-13(1–6) and 
[Pyr1]apelin-13(1–10) peptides were targeted using precursor ion m/z values of 370.214 (collision energy of 30) 
and 290.417 (collision energy of 22) respectively. The MS/MS analysis involved the same LC separation, but MS/
MS data were acquired at 17,500 resolution with an AGC of 1e6 ions, lowest m/z value of 100 and a max fill time 
of 200 ms.
Data availability
All data generated or analysed during this study are included in this published article.
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